Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Pfizer and AVANT Enter into Licensing and Development Agreement for Novel Therapeutic Vaccine Candidate for Brain Cancer
- NEW YORK & NEEDHAM, Mass. -- Pfizer, Inc (NYSE: PFE) and AVANT Immunotherapeutics (Nasdaq: AVAN), acting through its wholly-owned subsidiary Celldex Therapeutics, Inc. today announced that they have entered into an agreement under which Pfizer will be granted an exclusive worldwide license to a therapeutic cancer vaccine candidate, CDX-110, in...
- Research articles 2008-04-16
- PFIZER Inc. and Avant Immunotherapeutics.(agreement to develop animal vaccines)(Brief Article)
- PFIZER Inc. and Avant Immunotherapeutics have formed an agreement to develop animal vaccines. Pfizer is paying $2.5 million in up-front licensing ... PFIZER Inc. and Avant Immunotherapeutics have formed an agreement to develop animal vaccines. Pfizer is paying $2.5 million in up-front licensing...
- Research articles 2000-12-04
- nStor and Avant Networks Sign Distributor Agreement; nStor Selected by Avant to Bring Innovative, World-Class Storage Solutions to Asian Marketplace
- Business Editors & High-Tech Writers
- Research articles 2001-04-25
- Monterey Design Signs Agreement With Leading Distributor of EDA Products in Taiwan; Avant Technologies Selected as Exclusive Distributor Based On Proven Track Record of EDA Expertise
- Business Editors/High-Tech Writers
- Research articles 2002-10-01
- Avant Signs Agreement with Pfizer for Development of Animal Health Vaccines
- NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today the signing of an extended collaborative research and development agreement with Pfizer Inc aimed at the discovery and development of vaccines to protect animals. The collaboration will employ vaccine technologies owned by AVANT.
- Research articles 2006-10-04
Additional Resources
- Synopsys buys Avant! (Briefly).
- Synopsys Inc., a technology leader for complex integrated circuit IC design, has entered into a definitive agreement to acquire Avant! Corp., a leader in physical design and transistor-level design tools for the IC industry. Synopsys Inc., a technology leader for complex integrated circuit...
- Research articles 2002-02-01
- AVANT to Develop an Oral Anthrax and Plague Vaccine for U.S. Department of Defense
- Business Editors & Health/Medical Writers BIOWIRE2K NEEDHAM, Mass.--BUSINESS WIRE--Jan. 22, 2003 AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced it has been awarded a subcontract to develop for the U.S. Department of Defense an oral combination vaccine against anthrax and plague using AVANT's proprietary vaccine technologies. Under the...
- Research articles 2003-01-22
- Avant!'s FrontLine is broadline buy - Avant! acquires FrontLine Design Automation - Company Business and Marketing
- Sunnyvale, Calif.--Moving into IC logic design with its third acquisition in 45 days, Avant! Corp. reached a definitive agreement to merge with FrontLine Design Automation, a three-year-old privately held software company specializing in high-performance hardware description language HDL simulation technology.
- Research articles 1996-10-14
- AVANT Announces Latest GSK Report on Sales of Rotarix® Evidences Disagreement on Royalty Rate in Patent Countries
- NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today announced that GlaxoSmithKline GSK paid royalties on GSK's sales of RotarixR rotavirus vaccine in Australia and certain European countries at the lower of two royalty rates under their 1997 license agreement. GSK's decision to pay the lower royalty rate (which is...
- Research articles 2006-09-20
- 3M Collaborates with AVANT on Vaccine Adjuvants
- ST. PAUL, Minn. -- 3M Drug Delivery Systems announces the signing of a non-exclusive license agreement with Celldex Therapeutics, Inc. (a wholly-owned subsidiary of AVANT Immunotherapeutics). Under the agreement, 3M will provide its patented toll-like receptor TLR agonist compounds to Celldex for an undisclosed licensing fee, milestones and royalties.
- Research articles 2008-06-11
- AVANT Immunotherapeutics, Inc. and Celldex Therapeutics Schedule Joint Teleconference for Monday, October 22, 2007 at 9:00 AM EDT
- NEEDHAM, Mass. & PHILLIPSBURG, N.J. -- AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) and Celldex Therapeutics, Inc., a privately-held company, announced today that they will hold a joint teleconference on Monday, October 22 at 9:00 AM EDT to discuss the proposed merger agreement announced earlier this morning in a joint press release.
- Research articles 2007-10-22
- Chile: Aeromet to start flying nationwide.
- Chile: The Aeromet airline will start operating nationwide next November. It will sign a code share agreement with United Airlines after Chile and the US sign a new air transportation agreement by end October. At present only Lan Chile, Ladeco and Avant operate nationwide...
- Research articles 1999-09-27
- Acquisition Time in EDA - Mentor Graphics acquires CLK Computer-Aided Design - Company Business and Marketing - Brief Article
- Mentor Graphics revealed during a recent financial conference call that it had purchased Fremont, Calif.-based CLK Computer-Aided Design for its place and route technology. That deal followed close on the heels of Avant! Corp.'s agreement to buy Rochester, N.Y.-based Xynetix Design Systems Inc., broadening its back-end tool offering, particularly in...
- Research articles 1999-05-03
- AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. Announce Merger Agreement
- Creates NASDAQ-listed biopharmaceutical company with diversified pipeline addressing high-value indications within oncology, infectious and inflammatory diseases
- Research articles 2007-10-22
- Chartered Strikes EDA-IP Deal
- Milpitas, Calif.-Chartered Semiconductor Manufacturing has signed an agreement with four companies in the electronic design automation EDA and intellectual property IP business in an effort to create a seamless design environment for the production of integrated circuits on a 0.18-micron process. Cadence Design Systems, Synopsys Inc., Avant! Corp., and...
- Research articles 1999-03-08
- << Previous
- page 1 of 1
- Next >>
